Pictet Asset Management
KNSA icon

Pictet Asset Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Pictet Asset Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.9M Sell
608,650
-14,638
-2% -$759K 0.04% 385
2026
Q1 		$30M Sell
623,288
-164,232
-21% -$7.28M 0.03% 409
2025
Q4 		$32.5M Sell
787,520
-144,576
-16% -$5.8M 0.03% 410
2025
Q3 		$36.2M Sell
932,096
-52,501
-5% -$1.71M 0.03% 385
2025
Q2 		$27.2M Sell
984,597
-149,334
-13% -$3.8M 0.03% 434
2025
Q1 		$25.2M Hold
1,133,931
– – 0.03% 438
2024
Q4 		$22.4M Sell
1,133,931
-73,818
-6% -$1.68M 0.02% 470
2024
Q3 		$30.2M Sell
1,207,749
-95,967
-7% -$2.34M 0.03% 392
2024
Q2 		$24.3M Sell
1,303,716
-156,917
-11% -$2.94M 0.03% 421
2024
Q1 		$28.8M Sell
1,460,633
-110,183
-7% -$2.15M 0.03% 407
2023
Q4 		$27.6M Sell
1,570,816
-33,901
-2% -$557K 0.03% 403
2023
Q3 		$27.9M Buy
+1,604,717
New +$27M 0.03% 390

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Pictet Asset Management's KNSA Position: Q2 2026 in Review

Pictet Asset Management reduced its Kiniksa Pharmaceuticals (KNSA) stake by 2.3% in Q2 2026, selling an estimated $759K and leaving 608,650 shares worth $38.9M. The position accounts for 0.04% of the portfolio, ranked #385.

Pictet Asset Management first reported a position in KNSA in Q3 2023 and has held it in 12 quarters since. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Pictet Asset Management held 608,650 shares of Kiniksa Pharmaceuticals worth $38.9M as of Q2 2026.
  • Pictet Asset Management sold 14,638 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $759K.
  • Kiniksa Pharmaceuticals made up 0.04% of Pictet Asset Management's portfolio in Q2 2026, its #385 holding.
  • Pictet Asset Management first reported a position in Kiniksa Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.